AAV Immuno-Gene Therapy programme - Siren Biotechnology
Alternative Names: Universal AAV Immuno-Gene Therapy™Latest Information Update: 19 Jun 2023
Price :
$50 *
At a glance
- Originator Siren Biotechnology
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Brain cancer; Eye neoplasms